Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.

CYP2C19 inhibitors (not CYP3A4) induce phenoconversion and reduce clopidogrel clinical effectiveness in NM/RM/UM patients

A retrospective study of 3,242 CYP2C19-genotyped patients undergoing PCI evaluated the impact of co-prescribed CYP2C19 or CYP3A4 inhibitors on 12-month major atherothrombotic events (MAE). In NM/RM/UM patients treated with clopidogrel, co-prescription of a CYP2C19 inhibitor was associated with an adjusted HR of 2.22 (p=0.048) for MAE, suggesting significant phenoconversion. By contrast, CYP3A4 inhibitors did not significantly affect MAE in this group, contradicting the hypothesis of a major CYP3A4 contribution to phenoconversion.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This study provides an important clarification: CYP2C19 inhibition (not CYP3A4) drives clinically significant phenoconversion in genotyped NM clopidogrel patients. In practice, prescribers must be particularly vigilant about CYP2C19 inhibitors (omeprazole, fluconazole, fluvoxamine) in NM/RM/UM carriers on post-PCI clopidogrel, even if their genotype predicts good response.

Clinical impact : 2/3 · Evidence quality : 3/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 8/10